Xia Zhang-Yong, Wang Jing, Guo Jian-Wen, Zhang Rui, Li Jie-Xia, Zhong Jian-Bin, Luo Sai-Hua, Chen Guang-Sheng, Huang Gan, Zhao Qian-Shan
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Jul;36(7):821-826.
To study the safety of using Chinese drugs for breaking blood expelling stasis (CDBBES) in hypertension patients with intracerebral hemorrhage within 6 h, and to observe whether they would result in hematoma enlargement.
A prospective randomized double-blind controlled clinical study was employed. Totally 128 cerebral hemorrhage patients within 6 h were recruited from 8 research centers from October 2013 to March 2015, and finally 76 of them were included. These patients were assigned to 3 groups by simple random sampling, group A, B, and C. Patients in group A (26 cases) took whole CDBBES recipe (containing leeches and equivalent insects). Those in group B (25 cases) took CDBBES recipe (removing leech and gradfly). Those in group C (25 cases) took placebos. Medication lasted for 10 successive days. The hematoma enlargement rate within 24 h, the occurrence of adverse reactions and adverse events were observed. To guarantee the safety of this trial, an interim analysis of first level unblinding was used.
The hematoma enlargement rate was 11. 5% (3/26) in group A, 16. 0% (4/25) in group B, and 20. 0% (5/25) in group C. There was no statistical difference in the hematoma enlargement rate among the 3 groups (X² =0. 823, P =0. 682). Adverse reactions and adverse events occurred in 7 cases, 1 patient with acute myocardial infarction, 1 with chest op- pression and palpitation, 2 with diarrhea in group A. No patient had adverse reaction or adverse event in group B. And diarrhea occurred in 3 patients of group C.
The interim analysis of first level unblinding showed that hematoma enlargement within 6 h was not resulted from using CDBBES.
研究高血压脑出血患者6小时内使用活血化瘀类中药的安全性,观察其是否会导致血肿扩大。
采用前瞻性随机双盲对照临床研究。2013年10月至2015年3月,从8个研究中心招募了128例6小时内的脑出血患者,最终纳入76例。这些患者通过简单随机抽样分为A、B、C三组。A组(26例)服用活血化瘀类中药全方(含水蛭等虫类药);B组(25例)服用活血化瘀类中药方(去水蛭、虻虫);C组(25例)服用安慰剂。连续用药10天。观察24小时内血肿扩大率、不良反应及不良事件的发生情况。为保证本试验的安全性,采用一级揭盲的中期分析。
A组血肿扩大率为11.5%(3/26),B组为16.0%(4/25),C组为20.0%(5/25)。三组血肿扩大率差异无统计学意义(X² =0.823,P =0.682)。A组发生不良反应及不良事件7例,其中急性心肌梗死1例、胸闷心悸1例、腹泻2例;B组无患者发生不良反应及不良事件;C组有3例患者发生腹泻。
一级揭盲的中期分析表明,6小时内血肿扩大并非使用活血化瘀类中药所致。